Buja, Alessandra
De Luca, Giuseppe
Gatti, Maura
Cozzolino, Claudia
Rugge, Massimo
Zorzi, Manuel
Gardi, Mario
Sepulcri, Matteo
Bimbatti, Davide
Baldo, Vincenzo
Maruzzo, Marco
Basso, Umberto
Zagonel, Vittorina
Article History
Received: 12 September 2022
Accepted: 5 December 2022
First Online: 19 December 2022
Declarations
:
: This study was approved by the Ethics Committee of the Istituto Oncologico Veneto—IRCCS on February 17, 2020. All methods were performed in accordance with Cost of Illness study guidelines (Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011 Aug;29(8):653–71).
: Not applicable.
: This is an observational study. The study complied with the Declaration of Helsinki and with the resolution No. 9/2016 of the Italian Guarantor for the Protection of Personal Data, which also confirmed the permission of processing personal data for medical, biomedical and epidemiological research, and that data concerning people’s health status can be used in aggregate form in scientific studies. To ensure confidentiality and anonymity, the Veneto Regional Authority removes all direct identifiers and replaces them with a code number in all datasets to retain the opportunity to link data from different administrative databases. The data analysis was performed on anonymous aggregated data with no chance of individuals being identifiable. In this case, according to No. 9/2016 of the Italian Guarantor for the Protection of Personal Data, it is possible to not collect written consent from patients. No minors or illiterate participants were involved in this study. All the procedures were approved by the Ethics Committee of the Istituto Oncologico Veneto—IRCCS on February 17, 2020.
: The authors declare that they have no competing interests.